Scientific intelligence record
Experience 2.0
Mitochondrial-derived peptide
Also known as: Mitochondrial ORF of the 12S rRNA-c, MOTS-c peptide
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Experimental work links it to cellular stress responses, AMPK-related metabolism, nuclear signaling, exercise adaptation, and age-associated physiology.
Record status
Traceability partial
Last meaningful update: 9/8/2026
Ranked research corpus
270
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
270 matching records · ranked 2026-09-18
Page 1 of 11
Europe PMC · 2027 · PMID 42633281 · DOI 10.1016/j.bioactmat.2026.06.010
preclinical-animal
Europe PMC · 2026 · PMID 40753494 · DOI 10.1080/00207454.2025.2542883
preclinical-animal
Europe PMC · 2026 · PMID 42650220 · DOI 10.3390/antiox15080956
preclinical-animal
Europe PMC · 2026 · PMID 41710402 · DOI 10.3389/fendo.2026.1732329
laboratory-mechanistic
Europe PMC · 2026 · PMID 41945630 · DOI 10.20945/2359-4292-2026-0031
contextual-unclassified
Europe PMC · 2026 · PMID 42349896 · DOI 10.1113/ep093298
preclinical-animal
Europe PMC · 2026 · PMID 41803858 · DOI 10.1186/s12917-026-05400-3
preclinical-animal
Europe PMC · 2026 · PMID 42166398 · DOI 10.1159/000552202
human-observational
Europe PMC · 2026 · PMID 42576277 · DOI 10.1080/17501911.2026.2715309
preclinical-animal
Europe PMC · 2026 · PMID 41593376 · DOI 10.1007/s00210-026-05018-0
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.20944/preprints202604.0328.v1 · DOI 10.20944/preprints202604.0328.v1
preclinical-animal
Europe PMC · 2026 · PMID 42193373 · DOI 10.3390/biomedicines14051048
human-observational
Europe PMC · 2026 · PMID 42142418 · DOI 10.1016/j.redox.2026.104204
preclinical-animal
Europe PMC · 2026 · Source ID doi:10.64898/2026.06.22.733272 · DOI 10.64898/2026.06.22.733272
preclinical-animal
Europe PMC · 2026 · PMID 41764620 · DOI 10.2174/0109298665430028251230103831
preclinical-animal
Europe PMC · 2026 · PMID 41654147 · DOI 10.1016/j.freeradbiomed.2026.01.064
preclinical-animal
Europe PMC · 2026 · PMID 42128272 · DOI 10.1016/j.lfs.2026.124452
preclinical-animal
Europe PMC · 2026 · PMID 41520850 · DOI 10.1016/j.freeradbiomed.2026.01.002
preclinical-animal
Europe PMC · 2026 · PMID 42633878 · DOI 10.1016/j.ejphar.2026.179261
preclinical-animal
Europe PMC · 2026 · PMID 42611943 · DOI 10.7554/elife.87615
preclinical-animal
Europe PMC · 2026 · PMID 42126770 · DOI 10.1007/s11255-026-05198-x
contextual-unclassified
Europe PMC · 2026 · PMID 42266945 · DOI 10.3389/fmed.2026.1838178
preclinical-animal
Europe PMC · 2026 · PMID 42228044 · DOI 10.1007/s11033-026-12064-7
preclinical-animal
Europe PMC · 2026 · PMID 41811086 · DOI 10.5603/fhc.110668
preclinical-animal
Europe PMC · 2026 · PMID 42153537 · DOI 10.1080/15548627.2026.2677180
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.
European Medicines Agency medicines databaseNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.
Drugs@FDA: FDA-Approved DrugsMOTS-c evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). MOTS-c — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/mots-c
AMA / Vancouver
World Peptide Foundation. MOTS-c — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/mots-c
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
270
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
MOTS-c no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2015 · study · Temporal status not established
peer_reviewed_research
2018 · study · Temporal status not established
peer_reviewed_research
2018 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2020 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2025 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
5 represented evidence records
Years represented: 2015, 2018, 2019, 2020, 2022
Publishing organizations appearing in records: peer_reviewed_research
5 represented evidence records
Years represented: 2015, 2020, 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 2015, 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 2020, 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2018, 2019, 2020
Publishing organizations appearing in records: peer_reviewed_research
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the MOTS-c evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/8/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/8/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:24:32 AM
25 of 270 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OBJECTIVES: This study evaluated whether serum levels of mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) could provide prognostic insights in patients newly diagnosed with multiple myeloma (M …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In vitro studies demonstrated that oxidative stress induces MOTS-c levels and MOTS-c treatment reduces hypoxia-induced oxidative stress through activating antioxidants. CONCLUSIONS: The circulating MOTS-c is associated with an increased r …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Background Multiple sclerosis (MS) is a major global problem, and as its pathogenesis is understood more clearly, therapeutic options expand accordingly. The mitochondrial open reading frame of the 12S rRNA-c (MOTS …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (fol …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Here, we demonstrate that MOTS-c can be an effective treatment for GDM. A GDM mouse model was established by short term high-fat diet combined with low-dose streptozotocin (STZ) treatment while MOTS-c was administrated daily during pregnancy. ...In add …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Further research is required to define the effect of these variables on MDPs and to determine whether MDPs other than MOTS-c have exercise mimetic properties. MOTS-c treatment of young and aged mice improves exercise capacity/performance and leads to a …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In rat LIRI models, endothelial cells exhibited the most significant MOTS-c upregulation, correlating with barrier preservation and reduced oxidative stress. ...Exogenous MOTS-c administration in rats attenuated lung injury by reducing oxidative damage …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Mitochondrial-derived peptides (MDPs), encoded by mitochondrial DNA, play a cytoprotective role by helping preserve mitochondrial function and cell viability under stressful conditions. Humanin and its homologs and MOTS-c are two of several MDPs hypothesized to have …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
MOTS-c levels were measured by ELISA and its diagnostic value was evaluated by receiving operating characteristic curve analysis. ...The impact is dependent on MOTS-c's ability to regulate MYH9-actin-mediated mitochondrial homeostasis. CONCLUSION: M …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The 12S ribosomal RNA (MT-RNR1) gene harbors the sequence for MOTS-c, whereas the other seven MDPs [humanin and small humanin-like peptides (SHLP) 1-6] are encoded by the 16S ribosomal RNA gene. ...Consistent with this, treatment of rodents with humanin, MOTS …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Mitochondrial open reading frame of the 12S ribosomal RNA type-c (MOTS-c), a mitochondrial microprotein, has been described as a novel regulator of glucose and lipid metabolism. ...MOTS-c treatment improves systemic inflammation and skeletal mus …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
MOTS-c is a mitochondrial microprotein that improves metabolism. Here, we demonstrate CK2 is a direct and functional target of MOTS-c. ...Notably, a naturally occurring MOTS-c variant, K14Q MOTS-c, has reduced binding to CK2 …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
As a new member of the mitochondrial-derived peptide family, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) is regarding a peptide hormone that could reduce insulin resistance, prevent obesi …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Whereas the mitochondrial genome is regulated by factors encoded in the nucleus, the nuclear genome is currently not known to be actively controlled by factors encoded in the mitochondrial DNA. Here, we show that MOTS-c, a peptide encoded in the mitochondrial genome …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Mitochondrial open reading frame of the 12S rRNA type-c (MOTS-c) is the most unearthed peptide encoded by mitochondrial DNA (mtDNA). It is an important regulator of the nuclear genome during times of stress because it promotes an adaptive stress response to m …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Although recent clinical studies have suggested a possible link between MOTS-c and human cancer, the role of MOTS-c in tumorigenesis has yet to be investigated. ...In conclusion, this study reveals a crucial role of MOTS-c in OC and provi …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Here we report a sORF within the mitochondrial 12S rRNA encoding a 16-amino-acid peptide named MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) that regulates insulin sensitivity and metabolic …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
MOTS-c, a mitochondrial-derived peptide (MDP), is an essential regulatory mediator of cell protection and energy metabolism and is involved in the development of specific diseases. ...Exercise effectively upregulates the expression of MOTS-c, but the s …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) is a mitochondrial-derived peptide composed of 16 amino acids encoded by the 12S rRNA region of the mitochondrial genome. ...Nevertheless, MOTS-c has been used less frequently in disease treatmen …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Here, the focus is on the following issues: (i) the biological effects of mitochondrial-derived peptides (humanin, humanin-like peptides and MOTS-c) and their use in therapy, (ii) the abnormal accumulation of beta-amyloid peptide within the mitochondrial matrix and …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Currently, eight MDPs have been published: humanin, MOTS-c, and SHLPs 1-6. This Review describes recent advances in microprotein discovery with a focus on MDPs. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Additionally, emerging exercise mimetics such as the mitochondrial-derived peptide MOTS-c and myostatin inhibitors are highlighted for their roles in increasing muscle mass, the browning of white adipose tissue, and improving systemic metabolic function. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
On the contrary, no mitochondrial-encoded factors are known to actively regulate nuclear gene expression. MOTS-c (mitochondrial open reading frame of the 12S ribosomal RNA type-c) is a recently identified peptide encoded within the mitochondrial 12S ribosomal RNA ge …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Among MDPs, mitochondrial ORF of the 12S rRNA type-c (MOTS-c) is the most associated with exercise. MOTS-c expression levels increase in skeletal muscles, systemic circulation, and the hypothalamus upon exercise. ...This review briefly summarize …
2 represented evidence records
Years represented: 2022, 2025
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2023, 2024
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2015, 2024
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2020, 2021
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2015, 2024
Publishing organizations appearing in records: peer_reviewed_research